Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market

Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market
全球单克隆抗体、疫苗及其他癌症免疫疗法市场研究报告

发布时间：2007.5.1

sample pages

摘要

Cancer is the second most common cause of death in the industrialized world. At this time, treatment for cancer focuses on some combination of surgery, radiation, and chemotherapy.
But over the next five years, treatment is going to dramatically change. as detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market from Kalorama Information. One of the most promising new approaches in modern cancer treatment is immunotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. Immunological and biotherapy treatments which target therapy are a fraction of total cancer treatment revenues at the current time, but will soon make up the lion’s share of the total cancer therapy market. The novel treatments covered in this report includes:

Monoclonal Antibodies cloned antibody molecules produced by specialized tissue cell culture lines, that specifically bind with target antigens and could therefore be used in several ways to treat cancer. Antibodies can be used to deliver a cytotoxic drug preferentially to the cancer cell and thus minimize drug interactions with normal cells.
Vaccines that can develop resistance to cancer in populations. Already, vaccines that deal with pre-cancer infections such as Gardasil and soon-to be-released Cerevix are attracting attention. More therapeutic vaccines are in Phase III trial at this time.
To a more limited extent, Interleukins and Interferons are utilized and their use and market potential is described in the report.
Other Biotherapy including treatments such as treatments such as; antisense oligonucleotides, apoptosis, or programmed cell death, protein and polypeptide growth factors, methylation, p53 tumor suppressor proteins, ras proteins, regulatory enzymes and other therapies.
Clearly immunologic treatments have moved beyond theory and Kalorama Information takes this growing sector and establishes a clear market picture. This global report details:
Market Share for companies in this area.
Company Profiles of key competitors and their Current Products.
Global Data: US, Europe, Japan and Rest of World revenues and forecasts.
Forecasts to 2011 for sales of Monoclonal Antibodies, Vaccines and other biotherapeutic treatment segments.
Extensive Review of New Product Pipeline.
Product managers, Marketing executives, Advertising and financial executives are among those who will find this information on these novel cancer treatments essential.

目录及图表

Chapter One: Executive Summary

Overview
Market Size and Growth
Markets by Geographical Segments
U.S. Market
European Market
Japanese Market
ROW Market

Market Data by Indication
Competitive Analysis
Scope and Methodology
Chapter Two: Introduction

Overview
Monoclonal Antibodies
Interleukins/Interferons
Vaccines
Other Biotherapy
Antisense Oligonucleotides
Apoptosis
Growth Factors
Methylation
P53
Ras Protein Drugs
Regulatory Enzymes

Description of Products
Monoclonal Antibodies
Avastin (bevacizumab)
Campath (alemtuzumab)
Erbitux (cetuximab)
Herceptin (trastuzumab)
Mylotarg (gemtuzumab ozogamicin)
Panorex (edrecolomab)
Rituxan (rituximab)

Interleukins/Interferons
Alferon-N
Infergen
Intron A
Proleukin
Roferon A

Vaccines
Gardasil
M-Vax
Melacine
OncoTICE
OncoVax
Pacis
TheraCys (ImmuCyst)

Other Biotherapy
Enzyme Adenosine Deaminase
Tyrosine Kinases
Proteasome Inhibitors

Newly Approved Immunotherapy Drugs
Chapter Three: Research and Development

Pipeline For BioTherapeutic/Immunologic Treatments
Avastin
Cervarix
Dimericine
Genta
Junovan
Tykerb
M-Vax
Panitumumab
Provenge
Tasigna
Atrasentan (Xinlay)
Rituxan
Advexin
Allovectin-7
Alvocidib
Insegia
Affinitak
AMG 162
Anti-gastrin Immunogen G17DT
Avicine
BAY 43-9006 (Nexavar)
Biovaxid
Ceplene
Cintredekin
Cloretazine
CoFactor (ANX-510)
Cotara
DCVax
Enzastaurin
Erbitux
FavId
Glufosfamide
GMK vaccine
G-Top 99 / MyVax Personalized Immunotherapy
GVAX vaccine for prostate cancer
HuMax-CD4 (zanolimumab)
Ipilimumab
Iressa
Ixabepilone
Javlor
Neovastat
Onconase
Oncophage
OncoVAX
OvaRex
PANVAC-VF
PEG-Intron
PF-3512676
Phenoxodiol
PTK787/ZK 222584
Rencarex
Romidepsin
Tarceva (erlotinib)
Telcyta A GST P1-1
Temsirolimus
Tesmilifene
Thymitaq
TransMID
Urocidin
Virulizin
Xcytrin
XL119
Yondelis
Zactima
Stimuvax
Chapter Four: Market Data

Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
European Market
Japanese Market
ROW Market
Market Data by Indication
Competitive Analysis
Chapter Five: Corporate Profiles

Introduction
Amgen, Inc
Biogen IDEC, Inc
Bristol-Myers Squibb Company/Oncology
Genentech, Inc
GlaxoSmithKline plc
Merck & Company, Inc.
Novartis Pharmaceuticals Corporation/Oncology
Roche
Sanofi-Aventis
TAP Pharmaceutical Products, Inc.
Table of Exhibits
Chapter One: Executive Summary

Figure 1-1  Immunological and Biotherapy Treatments as Percentage of Total Cancer Treatment Market, 2006 and 2011
Figure 1-2: World Cancer Immunotherapy Market, 2006  2011
Figure 1-3 World Cancer Immunotherapy Market Estimated Products Sales by Region, 2006
Figure 1-4: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006
Chapter Two: Introduction

Table 2-1 Monoclonal Antibodies
Table 2-2: Interleukin/Interferon
Table 2-3: Vaccines
Table 2-4: Other Biotherapy
Table 2-5: Newly Approved Immunotherapy/Biologic Agents
Chapter Three: Research and Development

Table 3-1:Cancer Immunotherapy and Biotherapy Products in Late Stage
Development (Product, Developer, Current Phase, Cancer Type, and
Earliest Approval Date)
Chapter Four: Market Data

Table 4-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of  dollars at the manufacturers level)
Figure 4-1: World Cancer Immunotherapy Market, 2004-2011  (in millions of dollars at the manufacturers level)
Table 4-2: World Cancer Immunotherapy Market; Market by Product Type  (Monoclonal Antibodies, Interleukins/Interferons, Vaccines and Other Biotherapy), 2004-2011
Figure 4-2: World Cancer Immunotherapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
Figure 4-3: World Cancer Immunotherapy Market  Market by Product Type and Percent Distribution, 2004-2011
Figure 4-4: World Cancer Immunotherapy Market Market by Product Type and Percent Market Share, 2006
Figure 4-5: World Cancer Immunotherapy Market  Market by Product Type and Percent Market Share, 2011
Table 4-3: World Cancer Immunotherapy Market Estimated Products Sales by  Region (U.S., Europe, Japan, Rest of World), 2004-2011  (in million of dollars at  the manufacturers level) Estimated Revenues
Figure 4-6: World Cancer Immunotherapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
Figure 4-7: World Cancer Immunotherapy Market Estimated Products Sales  by Region, 2006
Figure 4-8: World Cancer Immunotherapy Market Estimated Products Sales  by Region, 2011
Table 4-4: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006  (in million of dollars at the manufacturers level)
Figure 4-9: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006
Table  4-5: World Cancer Immunotherapy Market Leading Suppliers Shares by  Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
Figure 4-10: World Cancer Immunotherapy Market Leading Suppliers Market Share, Estimated 2006
Figure 4-11: World Cancer Immunotherapy Market Leading Suppliers Market Share, Projected 2011
Table 4-6: World Cancer Immunotherapy Market Top Cancer Immunotherapy Products by Estimated Sales and Percent of Market, 2006 (in million of dollars at  the manufacturers level)
Figure 4-12: World Cancer Immunotherapy Market Top Cancer Immunotherapy  Products by Estimated Sales and Percent of Market, 2006
Chapter Five: Corporate Profiles